Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo

Journal of Immunotherapy

Volumn 35, Issue 3, 2012, Pages 276-282

  Liu, Chengwen ^a   Lewis, Carol M ^a   Lou, Yanyan ^a   Xu, Chunyu ^a   Peng, Weiyi ^a   Yang, Yan ^a   Gelbard, Alexander H ^a   Lizée, Gregory ^a   Zhou, Dapeng ^a   Overwijk, Willem W ^a   Hwu, Patrick ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

adoptive cell transfer (ACT); anti CD40 mAb; immunotherapy

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN GP 100; INTERLEUKIN 2; MELANOCYTE PROTEIN PMEL 17; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD40; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; BONE MARROW CELLS; CELL LINE; FEMALE; GP100 MELANOMA ANTIGEN; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; T-LYMPHOCYTES;

EID: 84863382868     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31824e7f43     Document Type: Article

References (36)

1. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3:666-675. (Pubitemid 37328821)
2. Plautz GE, Bukowski RM, Novick AC, et al. T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology. 1999;54:617-623; discussion 23-24.
3. Cameron RB, Spiess PJ, Rosenberg SA. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J Exp Med. 1990;171:249-263. (Pubitemid 20040613)
4. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233:1318-1321. (Pubitemid 16002234)
5. Kwak LW, Neelapu SS, Bishop MR. Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. Semin Oncol. 2004;31:37-46. (Pubitemid 38209503)
6. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumorinfiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86:1159-1166. (Pubitemid 24249302)
7. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990;323:570-578. (Pubitemid 20260084)
8. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999;5:677-685. (Pubitemid 29289432)
9. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001;24:363-373. (Pubitemid 32825868)
10. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99:16168-16173. (Pubitemid 35462767)
11. Curtsinger JM, Schmidt CS, Mondino A, et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol. 1999;162:3256-3262. (Pubitemid 29313572)
12. Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol. 2010;22:333-340.
13. Sikora AG, Jaffarzad N, Hailemichael Y, et al. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol. 2009; 182:7398-7407.
14. Curtsinger JM, Valenzuela JO, Agarwal P, et al. IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol. 2005;174:4465-4469.
15. Saemann MD, Diakos C, Kelemen P, et al. Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3. Am J Transplant. 2003;3:1341-1349. (Pubitemid 37288077)
16. Elgueta R, Benson MJ, de Vries VC, et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229:152-172.
17. Bishop GA, Moore CR, Xie P, et al. TRAF proteins in CD40 signaling. Adv Exp Med Biol. 2007;597:131-151.
18. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 2003;10:1-13. (Pubitemid 36222071)
19. van Mierlo GJ, den Boer AT, Medema JP, et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA. 2002;99:5561-5566. (Pubitemid 34411588)
20. Lou Y, Wang G, Lizee G, et al. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 2004;64:6783-6790. (Pubitemid 39297942)
21. Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998;188:277-286. (Pubitemid 28357756)
22. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198:569-580. (Pubitemid 37040391)
23. Murphy WJ, Welniak L, Back T, et al. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol. 2003;170:2727-2733. (Pubitemid 36245667)
24. Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science. 2002;297:2060-2063.
25. Loskog AS, Eliopoulos AG. The Janus faces of CD40 in cancer. Semin Immunol. 2009;21:301-307.
26. Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev. 2009;229:88-100.
27. Shahinian A, Pfeffer K, Lee KP, et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science. 1993;261:609-612. (Pubitemid 23278372)
28. Borriello F, Sethna MP, Boyd SD, et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity. 1997;6:303-313. (Pubitemid 27148597)
29. Yee C. Adoptive therapy using antigen-specific T-cell clones. Cancer J. 2010;16:367-373.
30. Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004;173:7125-7130. (Pubitemid 39628146)
31. Thompson JA, Figlin RA, Sifri-Steele C, et al. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2003;9:3562-3570. (Pubitemid 37169219)
32. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118:294-305.
33. Fonsatti E, Maio M, Altomonte M, et al. Biology and clinical applications of CD40 in cancer treatment. Semin Oncol. 2010;37:517-523.
34. Kedl RM, Jordan M, Potter T, et al. CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci USA. 2001;98:10811-10816. (Pubitemid 32878702)
35. Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184: 747-752. (Pubitemid 26324129)
36. Guizetti J, Schermelleh L, Mantler J, et al. Cortical constriction during abscission involves helices of ESCRT-IIIdependent filaments. Science. 2011;331:1616-1620.